Belimumab, a recombinant human IgG1-λ monoclonal antibody against B lymphocyte stimulator (BLyS, also known as BAFF), is a biologic agent approved for the treatment of patients with active SLE despite ongoing standard of care therapy [25–27]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.